Incyte Management
Management criteria checks 4/4
Incyte's CEO is Herve Hoppenot, appointed in Jan 2014, has a tenure of 10.42 years. total yearly compensation is $16.66M, comprised of 7.8% salary and 92.2% bonuses, including company stock and options. directly owns 0.15% of the company’s shares, worth $21.01M. The average tenure of the management team and the board of directors is 8.4 years and 7.4 years respectively.
Key information
Herve Hoppenot
Chief executive officer
US$16.7m
Total compensation
| CEO salary percentage | 7.8% |
| CEO tenure | 10.4yrs |
| CEO ownership | 0.2% |
| Management average tenure | 8.4yrs |
| Board average tenure | 7.4yrs |
Recent management updates
Recent updates
Incyte: The Worst Has Been Avoided
Jun 16It's Probably Less Likely That Incyte Corporation's (NASDAQ:INCY) CEO Will See A Huge Pay Rise This Year
Jun 06
We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings
May 07Take Care Before Diving Into The Deep End On Incyte Corporation (NASDAQ:INCY)
May 03Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)
Apr 26Incyte: A Potential GARP Superstar
Feb 27Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today
Feb 02Here's Why We Think Incyte (NASDAQ:INCY) Might Deserve Your Attention Today
Oct 31Knight's affiliate files for Brazilian approval of cancer drug tafasitamab
Oct 07Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart
Sep 29Incyte drug Pemazyre to treat rare cancer cholangiocarcinoma approved in Australia
Sep 15Incyte wins approval of Pemazyre for rare blood cancer
Aug 26Incyte Q2 results beat on top and bottom lines as net income soars 27%; shares down 6%
Aug 02With EPS Growth And More, Incyte (NASDAQ:INCY) Makes An Interesting Case
Jul 27Incyte Corp. Should Move Higher (Technical Analysis)
Jul 18Incyte: Growth Drivers Are Coming
Jun 17Incyte Is A Buy As Ruxolitinib Ramps Revenue And Pipeline Matures
Apr 14Incyte: All Atention On Opzelura
Mar 21Incyte: Still Has Room To Grow
Jan 24Incyte: The Right Time To Buy The Stock
Dec 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$745m |
| Dec 31 2023 | US$17m | US$1m | US$598m |
| Sep 30 2023 | n/a | n/a | US$425m |
| Jun 30 2023 | n/a | n/a | US$366m |
| Mar 31 2023 | n/a | n/a | US$324m |
| Dec 31 2022 | US$17m | US$1m | US$341m |
| Sep 30 2022 | n/a | n/a | US$876m |
| Jun 30 2022 | n/a | n/a | US$945m |
| Mar 31 2022 | n/a | n/a | US$933m |
| Dec 31 2021 | US$14m | US$1m | US$949m |
| Sep 30 2021 | n/a | n/a | US$535m |
| Jun 30 2021 | n/a | n/a | US$338m |
| Mar 31 2021 | n/a | n/a | US$478m |
| Dec 31 2020 | US$16m | US$1m | -US$296m |
| Sep 30 2020 | n/a | n/a | -US$335m |
| Jun 30 2020 | n/a | n/a | -US$191m |
| Mar 31 2020 | n/a | n/a | -US$376m |
| Dec 31 2019 | US$15m | US$1m | US$447m |
| Sep 30 2019 | n/a | n/a | US$405m |
| Jun 30 2019 | n/a | n/a | US$306m |
| Mar 31 2019 | n/a | n/a | US$253m |
| Dec 31 2018 | US$9m | US$996k | US$109m |
| Sep 30 2018 | n/a | n/a | -US$109m |
| Jun 30 2018 | n/a | n/a | -US$102m |
| Mar 31 2018 | n/a | n/a | -US$167m |
| Dec 31 2017 | US$16m | US$967k | -US$313m |
Compensation vs Market: Herve's total compensation ($USD16.66M) is about average for companies of similar size in the US market ($USD13.52M).
Compensation vs Earnings: Herve's compensation has been consistent with company performance over the past year.
CEO
Herve Hoppenot (64 yo)
10.4yrs
Tenure
US$16,659,526
Compensation
Mr. Herve Hoppenot has been the Chairman of the Board at Incyte Corporation since May 2015 and as its Chief Executive Officer and was President since January 13, 2014 until June 05, 2023. Mr. Hoppenot serv...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 10.4yrs | US$16.66m | 0.15% $ 21.0m | |
| President and Head of Research & Development | 1.1yrs | US$16.57m | no data | |
| Executive VP & CFO | 5.3yrs | US$5.08m | 0.010% $ 1.4m | |
| Executive VP & GM of North America | 9yrs | US$4.09m | 0.0049% $ 677.3k | |
| Executive VP & Chief Medical Officer | 9.3yrs | US$5.63m | 0.0011% $ 157.3k | |
| VP of Finance | 2.3yrs | no data | 0.0032% $ 434.5k | |
| Executive VP & Head of Global Technical Operations | 8.4yrs | no data | 0.016% $ 2.2m | |
| Head of Investor Relations | no data | no data | no data | |
| Executive VP | less than a year | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Executive Vice President of Human Resources | 21.8yrs | US$1.31m | 0.021% $ 2.8m | |
| Executive VP of Global Medical Affairs | no data | US$3.30m | 0.0054% $ 751.8k |
8.4yrs
Average Tenure
60yo
Average Age
Experienced Management: INCY's management team is seasoned and experienced (8.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 10.4yrs | US$16.66m | 0.15% $ 21.0m | |
| Independent Director | 9.4yrs | US$478.76k | 0.0069% $ 950.5k | |
| Independent Lead Director | 22.6yrs | US$512.76k | 0.12% $ 16.2m | |
| Independent Director | 2.8yrs | US$454.76k | 0.0026% $ 362.8k | |
| Independent Director | 7.4yrs | US$466.26k | 0.0062% $ 858.0k | |
| Independent Director | 4.5yrs | US$482.26k | 0.0058% $ 804.2k | |
| Independent Director | 4.3yrs | US$454.76k | 0.0036% $ 489.7k | |
| Independent Director | 9.4yrs | US$479.76k | 0.0070% $ 968.4k | |
| Independent Director | 1.7yrs | US$444.76k | 0.0013% $ 178.0k |
7.4yrs
Average Tenure
64yo
Average Age
Experienced Board: INCY's board of directors are considered experienced (7.4 years average tenure).